BIOMAT Database Logo BIOMAT Database Logo

17beta-hydroxysteroid dehydrogenase type 1 and 2 expression in the human fetus. 2000

J Takeyama, and T Suzuki, and G Hirasawa, and Y Muramatsu, and H Nagura, and K Iinuma, and J Nakamura, and K I Kimura, and M Yoshihama, and N Harada, and S Andersson, and H Sasano
Department of Pathology, Tohoku University School of Medicine, Sendai, Miyagi, Japan. j-takeyama@patholo2.med.tohoku.ac.jp

The present study investigates the expression patterns of 17beta-hydroxysteroid dehydrogenase (17betaHSD) isozymes in human fetal tissues to understand how estrogenic activity is regulated in the human fetus. Using enzyme assay, high 17betaHSD activity was detected in the placenta and liver, and low levels of 17betaHSD activity were also present in the gastrointestinal tract and kidney. After Northern blot analysis, we detected the messenger ribonucleic acid for 17betaHSD type 1 (17betaHSD1) only in the placenta, whereas that for 17betaHSD type 2 (17betaHSD2) was detected in the placenta, liver, gastrointestinal tract, and urinary tract at 20 gestational weeks. In RT-PCR analysis of the messenger ribonucleic acid transcripts, 17betaHSD 1 was predominantly expressed in the placenta, brain, heart, lung, and adrenal, whereas 17betaHSD2 expression was predominantly detected in the liver, gastrointestinal tract, and kidney. In addition, we detected 17betaHSD2 immunoreactive protein in surface epithelial cells of the stomach, absorptive epithelial cells of the small intestine and colon, hepatocytes of the liver, and interstitial cells surrounding the urinary tubules of the renal medulla. 17betaHSD2 in these tissues may be functioning in the prevention of in utero exposure of the fetus to excessive estradiol from the maternal circulation and amniotic fluids.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D008297 Male Males
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D005260 Female Females
D005333 Fetus The unborn young of a viviparous mammal, in the postembryonic period, after the major structures have been outlined. In humans, the unborn young from the end of the eighth week after CONCEPTION until BIRTH, as distinguished from the earlier EMBRYO, MAMMALIAN. Fetal Structures,Fetal Tissue,Fetuses,Mummified Fetus,Retained Fetus,Fetal Structure,Fetal Tissues,Fetus, Mummified,Fetus, Retained,Structure, Fetal,Structures, Fetal,Tissue, Fetal,Tissues, Fetal
D005456 Fluorescent Dyes Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. Flourescent Agent,Fluorescent Dye,Fluorescent Probe,Fluorescent Probes,Fluorochrome,Fluorochromes,Fluorogenic Substrates,Fluorescence Agents,Fluorescent Agents,Fluorogenic Substrate,Agents, Fluorescence,Agents, Fluorescent,Dyes, Fluorescent,Probes, Fluorescent,Substrates, Fluorogenic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

J Takeyama, and T Suzuki, and G Hirasawa, and Y Muramatsu, and H Nagura, and K Iinuma, and J Nakamura, and K I Kimura, and M Yoshihama, and N Harada, and S Andersson, and H Sasano
Ontogeny of 17beta-hydroxysteroid dehydrogenase type 2 mRNA expression in the developing mouse placenta and fetus.
October 1997, Molecular and cellular endocrinology,
J Takeyama, and T Suzuki, and G Hirasawa, and Y Muramatsu, and H Nagura, and K Iinuma, and J Nakamura, and K I Kimura, and M Yoshihama, and N Harada, and S Andersson, and H Sasano
Evolutionary analysis of 11beta-hydroxysteroid dehydrogenase-type 1, -type 2, -type 3 and 17beta-hydroxysteroid dehydrogenase-type 2 in fish.
September 2004, FEBS letters,
J Takeyama, and T Suzuki, and G Hirasawa, and Y Muramatsu, and H Nagura, and K Iinuma, and J Nakamura, and K I Kimura, and M Yoshihama, and N Harada, and S Andersson, and H Sasano
Expression of 17beta-hydroxysteroid dehydrogenase type 2 in pelvic endometriosis.
April 2007, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,
J Takeyama, and T Suzuki, and G Hirasawa, and Y Muramatsu, and H Nagura, and K Iinuma, and J Nakamura, and K I Kimura, and M Yoshihama, and N Harada, and S Andersson, and H Sasano
Structure and function of 17beta-hydroxysteroid dehydrogenase type 1 and type 2.
January 2001, Molecular and cellular endocrinology,
J Takeyama, and T Suzuki, and G Hirasawa, and Y Muramatsu, and H Nagura, and K Iinuma, and J Nakamura, and K I Kimura, and M Yoshihama, and N Harada, and S Andersson, and H Sasano
11Beta-hydroxysteroid dehydrogenase-type 2 evolved from an ancestral 17beta-hydroxysteroid dehydrogenase-type 2.
August 2010, Biochemical and biophysical research communications,
J Takeyama, and T Suzuki, and G Hirasawa, and Y Muramatsu, and H Nagura, and K Iinuma, and J Nakamura, and K I Kimura, and M Yoshihama, and N Harada, and S Andersson, and H Sasano
Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
January 2008, Current medicinal chemistry,
J Takeyama, and T Suzuki, and G Hirasawa, and Y Muramatsu, and H Nagura, and K Iinuma, and J Nakamura, and K I Kimura, and M Yoshihama, and N Harada, and S Andersson, and H Sasano
17Beta-hydroxysteroid dehydrogenase type 2 and dehydroepiandrosterone sulfotransferase in the human liver.
December 2000, Endocrine journal,
J Takeyama, and T Suzuki, and G Hirasawa, and Y Muramatsu, and H Nagura, and K Iinuma, and J Nakamura, and K I Kimura, and M Yoshihama, and N Harada, and S Andersson, and H Sasano
Expression of 17beta-hydroxysteroid dehydrogenase type 1 and type 2, P450 aromatase, and 20alpha-hydroxysteroid dehydrogenase enzymes in immature, mature, and pregnant rats.
July 1997, Endocrinology,
J Takeyama, and T Suzuki, and G Hirasawa, and Y Muramatsu, and H Nagura, and K Iinuma, and J Nakamura, and K I Kimura, and M Yoshihama, and N Harada, and S Andersson, and H Sasano
17Beta-hydroxysteroid dehydrogenase type 1, 2, 3, and 4 expression and enzyme activity in human anterior pituitary adenomas.
April 1999, The Journal of clinical endocrinology and metabolism,
J Takeyama, and T Suzuki, and G Hirasawa, and Y Muramatsu, and H Nagura, and K Iinuma, and J Nakamura, and K I Kimura, and M Yoshihama, and N Harada, and S Andersson, and H Sasano
Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol.
December 1998, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!